4 terminated. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 4 |
| Phase 1 | 1 | Terminated 1 |
Follow Malignant Neoplasm: new trials by email Literature Review of Malignant Neoplasm trials Research Report on Malignant Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Precision Medicine for Patients With Identified Actionable Mutations Investigational Agent, Supportive Care Regimens, Next Gen Sequencing Report - Solid Tumor, Lymphoma | Phase 2 | Terminated | Wake Forest University Health Sciences | 45 | 2020-04-22 | 2024-07-03 |
| Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer recombinant human hyaluronidase - Lymphedema, Malignant Neoplasm | Phase 1 / Phase 2 | Terminated | Stanford University | 3 | 2013-12-01 | 2017-03-21 |
| Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies Total-body irradiation, Donor lymphocytes infusion (DLI), Cyclophosphamide - Malignant Neoplasm | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 4 | 2013-05-17 | 2025-05-16 |
| Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery trastuzumab, laboratory biomarker analysis - Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder | Phase 2 | Terminated | National Cancer Institute (NCI) | 4 | 2007-05-01 | 2019-08-20 |
Neoplasms (4) · Bile Duct Neoplasms (1) · Gallbladder Neoplasms (1) · Lymphedema (1) · Lymphoma (1) · Multiple Myeloma (1)
Hemic and Lymphatic Diseases (2) · Lymphatic Diseases (2) · Bile Duct Diseases (1) · Biliary Tract Diseases (1) · Biliary Tract Neoplasms (1) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Gallbladder Diseases (1) · Hematologic Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1)
Cyclophosphamide (1) · Drugs, Investigational (1) · Mycophenolic Acid (1) · Tacrolimus (1) · Trastuzumab (1) · Whole-Body Irradiation (1)
National Cancer Institute (NCI) (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · Stanford University (1) · Wake Forest University Health Sciences (1)
United States (4)
Ahmed Kaseb (1) · Dolores Grosso, DNP, CRNP (1) · Mark Pegram (1) · Stanley Rockson (1) · Stefan Grant, MD (1)
N01CM62202 (1), P30CA012197 (1), P30CA124435 (1)